Ranbaxy gets U.S. FDA approval for Cefadroxil powder

Friday, 28 March 2003, 08:00 Hrs
Printer Print Email Email
NEW DELHI: India's pharma major Ranbaxy Laboratories Ltd (RLL) has received approval from the U.S. Food and Drug Administration (FDA) to market its antibiotic Cefadroxil Powder for Oral Suspension USP, the company said.

The approval for oral suspension in 125 mg/5 ml, 250 mg/5 ml and 500 mg/5 ml strengths will see the antibiotic being marketed in the U.S. from June, the company said in a statement Thursday.

Patients who are allergic to either penicillin or cephalosporin antibiotics in any form would have to consult their doctor before taking Cefadroxil.

In 2002, the total sales of Cefadroxil totaled $37.7 million, while sales of the suspensions were $16.7 million, said Ranbaxy.
Source: IANS
GST rate cut to spur Bengaluru
The realty market in India's tech hub is set to grow as lower Goods and Services Tax (GST) rate..
Ola raises Rs 400 cr for electric
Leading ride-hailing cab aggregator Ola on Friday said it raised Rs 400 crore from its early in..
Fossil Group sells smartwatch
Global watch and accessories maker Fossil Group has announced to sell its smartphone technolog..
SpiceJet plans aggressive
Budget passenger carrier SpiceJet plans to aggressively expand its international networks to fl..